iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

- IBIO-201, a subunit vaccine combining SARS-CoV-2 spike protein antigens with the Company’s proprietary LicKM booster technology, advances to preclinical immunization studies with the potential for rapid manufacturing scale-up in iBio’s FastPharming SystemTM -

iBio Announces Second COVID-19 Vaccine Program

IBIO stock is hardly alone as a direct play on the coronavirus vaccine industry. Nevertheless, the company separates itself from the muck with its proprietary ability to scale up solutions.

IBIO Will Continue to Power Higher on Its Superior Scalability

A bet on IBIO stock is a bet on its plant-based research and its FastPharming processes. IBIO is one of the hottest stocks for good reason.

Why iBio Stock Will Extend Its Bullish Streak

Every investor is betting on a vaccine. Unfortunately, the case for IBIO stock is simply too speculative, as its trials remain under wraps.

Slim Vaccine Chances Make iBio Stock Too Speculative Here

Arcturus Therapeutics

Dynavax Technologies

Inovio Pharmaceuticals

Moderna

Novavax

Sorrento Therapeutics Inc

A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

7 Red-Hot Biotech Stocks Racing to Develop a Coronavirus Vaccine

Lincoln Park Capital made a huge bet on IBIO stock but will it be worth pursuing for investors who are currently on the sidelines?
The post Why Did Lincoln Park Capital Just Buy a Million Shares of iBio Stock?

Why Did Lincoln Park Capital Just Buy a Million Shares of iBio Stock?

Seemingly everyone in the investing world is betting on a coronavirus vaccine. Here's why IBIO stock is a great way to play that trend.

Buy iBio Stock as an Effective Vaccine Could Be Imminent

Alibaba

Co-Diagnostics

Humana

Block

We're starting to see some light at the end of the coronavirus tunnel, and investors are looking at stocks to buy for a post-crisis bump.

6 Top-Rated Stocks for a Post-Coronavirus-Crisis Bump

Traders have bought up a bunch of different biotech stocks as potential coronavirus cures. iBio is one that you should get rid of while it's still up.

There’s Little Reason to Hold Onto iBio Stock as it Chases Latest Virus

IBIO stock is a potentially rewarding stock if customers use its manufacturing processes to scale up production of a Covid-19 vaccine.
The post Why iBio Stock May Double or Triple in Value appeared first on InvestorPlace.

Why iBio Stock May Double or Triple in Value

IBIO stock is backed by promising technology in its efforts to make a coronavirus vaccine and a well-connected partner.

Why iBio Stock Could Soar 500% Above Its Current Levels

While there's always a chance investors see a huge move in iBio stock, it is simply too risk for many investors at this point. 
The post Even If You Want to Gamble, iBio Stock Is a Long Shot appeared first on InvestorPlace.

Even If You Want to Gamble, iBio Stock Is a Long Shot

IBIO stock gets attention because of iBio's foray into treating the coronavirus, but investors who want that exposure should look elsewhere.
The post iBio Stock Is Too Risky appeared first on InvestorPlace.

iBio Stock Is Too Risky

For investors in search of a novel coronavirus play, IBIO stock is looking increasingly like an extremely risky proposition.
The post It’s Still Best to Avoid IBIO Stock Despite Any Hype appeared first on InvestorPlace.

It’s Still Best to Avoid IBIO Stock Despite Any Hype

iBio, Inc. (NYSE: IBIO) shares are trading higher after the company provided an update on its COVID-19 vaccine manufacturing capacity.

Why iBio's Stock Is Trading Higher Today

Plant-based technology could be the key to a vaccine, and IBIO stockholders could benefit as the company develops potential solutions.
The post Outlook for IBIO Stock Remains Strong as World Seeks Covid Coutermeasures appeared first on InvestorPlace.

Outlook for IBIO Stock Remains Strong as World Seeks Covid Coutermeasures

- Company Expands Involvement in the Manufacturing USA® Network, Joining the National Institute for Innovation in Manufacturing Biopharmaceuticals -

iBio Estimates ~500 Million Dose Capacity for COVID-19 Vaccine from its FastPharming Facility™

It might not be a smooth ride, but IBIO stock's potential for gains is considerable. As such, investors willing to take on the risks might profit.

IBIO Stock Is Only Worth It for High-Risk Investors

- The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight - - The Nonprofit Will Help Lead Pre-Clinical Development and Clinical Trial Oversight -

iBio Expands COVID-19 Vaccine Collaboration to Include the Infectious Disease Research Institute

Main Street is reeling from coronavirus fears, but companies are working hard to kill it. IBIO stock will prosper from management successes.

IBIO Stock Dip is a 2020 Opportunity as a Bet on a Coronavirus Vaccine

IBIO stock is a hot coronavirus play, but don't count on it rising. The equity line of credit deal it signed with Lincoln Park Capital will likely lead to a lower stock price.

IBIO Stock may be a Hot Coronavirus Play, but Don’t Count on it Rising

IBIO stock looks like a worthy wager on exciting plant-based solutions. Here's what prospective investors need to consider before buying.

IBIO Stock Is a Unique and Worthy Biotech Bet

IBIO stock seems like a speculative trade and it’s exactly that. However, the terrible costs associated with fighting the coronavirus makes iBio extremely relevant.

It’s Tough to Admit, but Our New Normal Might Justify Buying IBIO Stock

A poor track record of no development or commercialization of any vaccine in the last decade, plus cash burn implies further equity dilution for IBIO stock. 
The post IBIO Stock Will Continue to Slide Lower After Speculative COVID-19 Surge appeared first on InvestorPlace.

IBIO Stock Will Continue to Slide Lower After Speculative COVID-19 Surge

iBio stock has some investors excited about a potential coronavirus cure. However, I simply view IBIO as a call option.

News for iBio Stock (IBIO)